|
|
|
| home > ebr > Autumn 2019 |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
|
|
In Brief
Vax Populi
EBR’s Industry Advisor, Emile Bellott, discusses the health achievement of vaccinations against infectious diseases in the post-industrial era, and how immunisation is essential to continue saving millions of lives every year.
|
|
|
|
|
Anti-Idiotypic Antibodies
Robust Method Development for Biologics and Biosimilars
Amanda Turner at Bio-Rad Laboratories examines the factors that enable the demand for biological medicines to evolve and expand, such as the introduction of lower-cost biosimilars, or the ongoing identification of new drug targets.
|
|
|
|
Preclinical Oncological Research
PET Technology and Tumour Progression
Dr Todd Sasser at Bruker BioSpin writes on how, with the advancements of PET scanning, oncologists are now better able to understand the development of cancers and tumours by better highlighting their morphology and other biomarkers.
|
|
|
|
Accelerating Process Development
Simply Good Monitoring
Paul Kroll and Alexandra Hofer at Securecell AG articulate how digitisation can accelerate process development in relation to the analysis of liquid samples.
|
|
|
|
High-Productivity Membrane Chromatography
The Next-Generation Purification of Monoclonal Antibodies
Gary Skarja at Merck examines the key developments in mAb manufacturing, including the benefits that address productivity and cost challenges in a singleuse format.
|
|
|
|
Challenges in Cellular, Tissue, and Gene Therapy Products
Drug Development Decisions
Cost control in drug development is always at the forefront of manufacturer’s minds, and Zeb Younes and Zaklina Buljovcic at PharmaLex examine how automation and decentralising the manufacturing process can help achieve this goal in the long run.
|
|
|
|
Developments in Artificial Intelligence
Focusing on Target Safety
Although in its infancy, Ruth Roberts at ApconiX describes how artificial intelligence can help reduce the cost and the amount of product failures in regard to drug development and creation.
|
|
|
|
Standardising Conditions for Extractables Testing
Exhaustive Extraction
Simone Carrara and Michele Vasso at Eurofins illustrate the importance of extractables and leachables to ensure drug efficacy, and that the product remains in optimal condition to interact with the patient.
|
|
|
|
|
|
Stem Cell Therapy
Recombinant Human Albumin
Cryopreservation and stem cell therapies are facing major changes and
advancements, Dr Phil Morton and Dr Daniel Shelly at Albumedix discuss
how albumin is useful across the cell therapy value chain.
|
|
|
|
Live Cell Transport
The Rising Star
The way in which we transport existing cell shipments is continuously being optimised, and Dr Corné Swart at Cellbox Solutions looks into these new devices that allow cells to survive compared to traditional methods.
|
|
|
|
|
|
Orphan Drugs and Rare Diseases
Patient Voices in the Industry
When considering the development of orphan drugs, the patients that suffer from the diseases and help process drug development in clinical trials also have to be considered, write William C Maier and Kelly Franchetti at ICON.
|
|
|
|
|
|
Biopharmaceutical Applications
The Advantages of Long-Read Sequencing
Jonas Korlach at Pacific Biosciences discusses the improvements in long-read sequencing technology, and the applications it may have in the discovery of new drugs.
|
|
|
|
Advances in Oncology
Advancing Liquid Biopsies
Mark Li at Resolution Bioscience examines why liquid biopsies are now becoming more commonly used compared to tissue biopsies.
|
|
|
|
|
|
The Potential of Medical Cannabis
Budding Opportunities for Pharma
Shifting attitudes towards cannabis-based medicines are making them more appealing to drug developers, which will in turn help patients who need these drugs, writes Callum McGuinn at Mewburn Ellis.
|
|
|
|
The Future of Clinical Research on Medical Cannabis
Trial by Fire
Dr Mark A Ware at Canopy Growth Corporation describes the changes in drug policy in recent times surrounding cannabis-based drugs, and the advantages they may have in treating patients.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
CPI to showcase results from BioStreamline project developing novel biotherapeutics
CPI, a UK-based technology innovation centre and a founding member of
the High Value Manufacturing Catapult, announced today that it will host
an event in Darlington, UK on 26 June 2019 to disseminate the results
of the £11.2M BioStreamline project to optimise the development of novel
therapeutics. During the event, the project partners — Lonza Biologics,
UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon),
Alcyomics Ltd and CPI — will showcase the results and discuss the
potential impact on overcoming some of the most significant shortcomings
of the biologics supply chain.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trials in Russia Orange Paper: Summary of Year 2013
Synergy Research Group
Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials.
Sponsors mention the following reasons for conducting studies in Russia:
1. Fast patient enrollment due to the centralized medical infrastructure.
2. Nearly 100% patient retention
3. GCP trained and certified Investigative Sites generating high quality data
4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >> |
|
 |
Industry Events |
 |
World Vaccine Congress Washington
27-29 September 2020, Walter E Washington Convention Center, Washington, US
The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >> |
|
|
